Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (2018 - 2025)

Arcturus Therapeutics Holdings' Shares Outstanding history spans 8 years, with the latest figure at $28.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 4.86% year-over-year to $28.4 million; the TTM value through Dec 2025 reached $28.4 million, up 4.86%, while the annual FY2025 figure was $28.4 million, 4.86% up from the prior year.
  • Shares Outstanding reached $28.4 million in Q4 2025 per ARCT's latest filing, up from $27.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $28.4 million in Q4 2025 to a low of $26319.0 in Q1 2021.
  • Average Shares Outstanding over 5 years is $22.9 million, with a median of $26.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: tumbled 99.89% in 2021, then soared 100442.72% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $26.4 million in 2021, then increased by 0.69% to $26.6 million in 2022, then rose by 1.03% to $26.8 million in 2023, then grew by 1.0% to $27.1 million in 2024, then grew by 4.86% to $28.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Shares Outstanding are $28.4 million (Q4 2025), $27.2 million (Q3 2025), and $27.1 million (Q2 2025).